The Dermatology Digest

FEBRUARY 27, 2024

Pelage Pharmaceuticals has closed a $16.75 We have uncovered a small molecule able to stimulate cellular metabolism to re-awaken hair follicle stem cells and spur new hair growth,” says William Lowry, PhD, scientific co-founder, Pelage Pharmaceuticals, in a news release.

Pharmaceutical 36

Pharmaceutical Treatments Hospital Clinic 36

The Dermatology Digest

MAY 15, 2024

Verrica Pharmaceuticals Inc. has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. FDA and Japan’s Pharmaceuticals and Medical Device Agency (PMDA) on the proposed design of the Phase 3 clinical trial. With a prevalence of approximately 22 million patients in the U.S.

Pharmaceutical 36

Pharmaceutical Clinic Sales Dermatology 36

Dermatology Times

APRIL 27, 2024

Keep up with the latest headlines in dermatology from the past week, including the appointment of All Detergent's first chief dermatology advisor, Incyte's acquisition of Escient Pharmaceuticals, and more.

Pharmaceutical 69

Pharmaceutical Dermatology 69

Dermatology Times

MAY 7, 2024

ASLAN Pharmaceuticals presented new data this morning, including a 90% EASI score reduction.

Pharmaceutical 68

Pharmaceutical 68

Dermatology Times

JANUARY 26, 2024

ICYMI, this week we had news about the completion of LEO Pharma's acquisition of Timber Pharmaceuticals, research pointing to melanoma overdiagnosis in White patients, artificial intelligence in skin cancer detection, and more.

Pharmaceutical 72

Pharmaceutical 72

Dermatology Times

FEBRUARY 29, 2024

The collaboration with Sato marks a continued effort of Arcutis to collaborate with pharmaceutical companies and license topical roflumilast in Asia.

Pharmaceutical 63

Pharmaceutical 63

The Dermatology Digest

APRIL 11, 2024

The first patient has been treated in Stamford Pharmaceuticals Inc.’s We believe there is an opportunity to further improve patient benefit in locally advanced BCC patients based on the current standard of care,” says Clement Leong, PhD, CEO of Stamford Pharmaceuticals, in a news release.

Pharmaceutical 36

Pharmaceutical Clinic Injections Dermatology 36

Dermatology Times

DECEMBER 19, 2023

Dr Bhutani presents the case of a 15-year-old female with long standing atopic dermatitis and discusses the importance of balancing parental preferences for "natural" agents with effective pharmaceutical options.

Pharmaceutical 36

Pharmaceutical Dermatitis Therapy 36

Dermatology Times

AUGUST 26, 2023

Keep up with the latest headlines in dermatology from the past week, including growing concerns of a dermatologist shortage in Ontario, LEO Pharma's acquisition of Timber Pharmaceuticals, and more. This week, we have also included a patient-forward rundown of top headlines to share with your patients.

Pharmaceutical 66

Pharmaceutical Dermatology 66

The Dermatology Digest

JANUARY 29, 2024

Medicaid and Medicare patient populations,” says Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, in a news release. “In “By securing a permanent J-Code for YCANTH, we have successfully reached a critical milestone in our commercial strategy that we expect will help us accelerate YCANTH utilization among the U.S.

Pharmaceutical 74

Pharmaceutical Office Medical Management 74

Renee Rouleau

JANUARY 19, 2024

Pharmaceutical and Medical Advancements Ingredients that have been traditionally used for non-skincare purposes are now finding their way into the beauty industry. For example, witch hazel , previously used in wound healing and as a vasoconstrictor in modern medicine, is now used for soothing the skin and reducing excess oil production.

Skincare 195

Skincare Innovations Ingredients Oily Skin 195

The Dermatology Digest

FEBRUARY 16, 2024

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) and Novartis Pharmaceuticals). Japan is the first country to approve dupilumab for CSU. This study met the primary and all key secondary endpoints.

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36

The Dermatology Digest

JANUARY 5, 2024

Zelsuvmi is expected to be commercially available during the second half of 2024, according to Ligand Pharmaceuticals. Approved in 2023 Verrica Pharmaceuticals’ Ycanth (cantharidin) was the first U.S.-approved Ligand Pharmaceuticals acquired all the assets of Novan, Inc. in September 2023. Novan developed Zelsuvmi.

Pharmaceutical 36

Pharmaceutical Office Medical Dermatology 36

The Dermatology Digest

MAY 14, 2024

TDD Talks to Brian Hilberdink, LEO Pharma’s EVP of North America, About Congenital Ichthyosis LEO Pharma recently acquired TMB-001 and other assets from Timber Pharmaceuticals following Timber’s Chapter 11 bankruptcy filing. Topical isotretinoin, even when applied to 90% of a patient’s body surface area, showed minimal systemic absorption.

Pharmaceutical 36

Pharmaceutical Skin Types Dermatology Therapy 36

Dermatology Times

OCTOBER 17, 2023

Hilary Baldwin, MD, offers her insights and hypotheses regarding the future of over-the-counter and pharmaceutical treatments, emphasizing the evolving landscape and the potential role of targeted microbiome-based approaches in the management of acne.

Pharmaceutical 36

Pharmaceutical Skincare Management Treatments 36

Dermatology Times

DECEMBER 18, 2023

Emphasizing the challenges of the steroid treatment cycle, the expert provides insights into integrating parental preferences for "natural" agents alongside effective pharmaceutical options. An expert in skin condition management discusses the case of a 13-year-old male with a prolonged history of AD and early-onset food allergies.

Pharmaceutical 36

Pharmaceutical Management Treatments 36

The Dermatology Digest

JANUARY 5, 2024

The last patient has been dosed in Part 2 of Verrica Pharmaceuticals Inc.’s s Phase 2 trial of VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. VP-315 is a chemotherapeutic administered intratumorally.

Pharmaceutical 36

Pharmaceutical Safety Office Clinic 36

The Dermatology Digest

FEBRUARY 5, 2024

Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising, Unfair Competition Verrica Pharmaceuticals Inc. has filed a lawsuit in the Eastern District of Pennsylvania against Dormer Laboratories Inc.,

Dermatology 36

Dermatology Pharmaceutical Technology Sales 36

The Dermatology Digest

FEBRUARY 8, 2024

Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., Food and Drug Administration (FDA) recently OKed a label update for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., Immunotherapy including cemiplimab (Libtayo, Regeneron Pharmaceuticals) has also brought hope to even the most difficult tumors,” he says.

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

Aesthetics Advisor

AUGUST 16, 2023

Novo traded at fresh highs as the Danish pharmaceutical company gained ground on the only European megacap that is larger than it. Makers of syringes for the pharmaceutical industry, Stevanato Group SpA and West Pharmaceutical Services Inc., also gained — rising 9.0% respectively.

Sales 36

Sales Pharmaceutical Marketing Medical 36

Aesthetics Advisor

AUGUST 22, 2023

The pharmaceutical industry doesn’t generate its desired profits by creating common drugs, even though they’re in high demand. In February, Akorn Pharmaceuticals, a company dedicated to producing generic drugs, filed for bankruptcy and had to close all its U.S. What produces higher profits are newer drugs , according to the U.S.

Pharmaceutical 36

Pharmaceutical Hospital Document Medical 36

The Dermatology Digest

JANUARY 4, 2024

Joint development for DMB-3115 was initiated in 2013 by Dong-A Socio Holdings and Meiji Seika Pharma, with exclusive commercialization rights granted to Intas Pharmaceuticals through a partnership announced in 2021. As a global subsidiary of Intas Pharmaceuticals, Accord BioPharma will be responsible for U.S. commercialization.

Pharmaceutical 36

Pharmaceutical Partnerships Clinic Safety 36

The Dermatology Digest

MAY 2, 2024

Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, a key pathway driving several allergic inflammatory diseases.

Pharmaceutical 74

Pharmaceutical Dermatitis Office Clinic 74

The Dermatology Digest

MARCH 28, 2024

Mr. Cotton currently serves on the board of directors of Eisai Pharmaceutical U.S., a research and development pharmaceutical company and subsidiary of Eisai Company, Ltd., Cotton received The Sagamore of the Wabash Award, one of the highest Indiana State honors from Indiana Governor Eric J.

Pharmaceutical 28

Pharmaceutical Technology Office Networking 28

Aesthetics Advisor

JANUARY 18, 2024

Currently there are three main categories of pharmaceutical agents used to treat or prevent ischemia issues: thrombolytics, antiplatelets, and anticoagulants. Is there not a safer and also effective natural option for helping patients besides the above categories of pharmaceuticals?

Pharmaceutical 36

Pharmaceutical Extractions Safety Clinic 36

The Dermatology Digest

APRIL 22, 2024

Notably, in patients that previously had an inadequate response to dupilumab, two-thirds achieved EASI-90 and vIGA 0 or 1 when treated with eblasakimab,” says Dr Carl Firth, Chief Executive Officer of Aslan Pharmaceuticals, in a news release. The interim data will be submitted for presentation at an upcoming scientific conference.

Pharmaceutical 36

Pharmaceutical Dermatitis Eczema Injections 36

The Dermatology Digest

FEBRUARY 26, 2024

Dupilumab (Dupixent, Sanofi, and Regeneron Pharmaceuticals), Lebrikizumab (Ebglyss, Almirall), and tralokinumab-ldrm (Adbry, Leo) were generally of intermediate effectiveness and among the safest but modestly increased the frequency of conjunctivitis.

Treatments 74

Treatments Dermatitis Pharmaceutical Clinic 74

Aesthetics Advisor

NOVEMBER 5, 2023

Brands like Centrum, Nature Made, and One-A-Day have also been enveloped by global giants like Glaxo Smith Kline, Otsuka Pharmaceuticals, and Bayer. The motivation becomes even murkier when these pharmaceutical behemoths, like Bayer, also have stakes in sectors such as agricultural chemicals. Moreover, it's not just Nestlé.

Pharmaceutical 36

Pharmaceutical Portfolios Branding Extractions 36

Aesthetics Advisor

FEBRUARY 11, 2024

Most medical schools still only teach how to identify late-stage autoimmune disease, not how to identify autoimmunity in its early stages and nor how to affect its progression through dietary, nutritional, pharmaceutical, or lifestyle applications. About the Author: Datis Kharrazian, Ph.D.,

Pharmaceutical 67

Pharmaceutical Diet Clinic Management 67

The Dermatology Digest

FEBRUARY 5, 2024

Food and Drug Administration has expanded the indication for dupilumab (Dupixent, Sanofi, Regeneron Pharmaceuticals, Inc.) Management in the form of diet, drugs, and/or esophageal dilation — known as the “3 Ds” — is recommended to prevent long-term complications.

Eczema 74

Eczema Pharmaceutical Management Diet 74

Kim Gallo Esthetics

MAY 31, 2023

Also known as pharmaceutical-grade , medical-grade skincare is exactly what it sounds like - products that are both developed and tested by medical professionals. Keep reading to find out why medical-grade skincare works better and which brand of professional-grade product is right for you. What is medical-grade skincare?

Medical Grade Skincare 195

Medical Grade Skincare Medical Skincare Skincare Brands 195

The Dermatology Digest

JANUARY 16, 2024

Food and Drug Administration (FDA) has updated the label for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc. and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. and Sanofi report. “We

Dermatitis 36

Dermatitis Pharmaceutical Safety Eczema 36

The Dermatology Digest

JANUARY 2, 2024

featured the pharmaceutical industry. In all, 28.7% featured the perspectives of patients; 11.7% featured academic institutions or non-profit organizations; 10.6% featured media outlets; 5.3% featured other health professionals; and 2.1%

Pharmaceutical 69

Pharmaceutical Dermatology Education Clinic 69

The Dermatology Digest

MARCH 10, 2024

Jason Hawkes, MD, MS, a dermatologist in Rocklin, CA, reviews currently available and emerging treatments for chronic spontaneous urticaria (CSU), including dupilumab (Dupixent, Sanofi, and Regeneron Pharmaceuticals), remibrutinib, Novartis’ investigational oral Bruton’s tyrosine kinase (BTK) inhibitor, other BTK inhibitors, interleukin (..)

Treatments 36

Treatments Pharmaceutical Dermatitis Eczema 36

Aesthetics Advisor

FEBRUARY 7, 2024

Carnosine Protects Against LA-Induced Oxidative Stress One benefit not expounded upon in the Pharmaceuticals paper is carnosine’s ability to reduce LA-induced oxidative stress. According to a 2021 paper, 13 daily intake of beta-alanine can raise the carnosine content of skeletal muscle by as much as 80%.

Pharmaceutical 36

Pharmaceutical Diet Retinol Injections 36

Associated Skin Care Professionals

AUGUST 14, 2023

Osmosis uses a unique combination of active ingredients that focuses on three important factors: our pharmaceutical-grade delivery system, because most aging occurs deep within the skin; our patented products that create real changes in the skin; and our unique inside-out approach that triggers collagen/elastin and plumps the volume of the face.

Vitamin C 52

Vitamin C Pharmaceutical Collagen Rosacea 52

The Dermatology Digest

MARCH 15, 2024

Sun Pharmaceutical Industries, Inc. recently rolled out a consumer-directed ad campaign for clascoterone cream 1% (Winlevi, Sun Pharma) featuring Upland, CA-based dermatologist Sandra Lee, MD, popularly known as Dr. Pimple Popper. The new campaign focuses on the role of sebum as a main cause of acne. WINLEVI is the first and only U.S.

Sebum 36

Sebum Document Pharmaceutical Education 36